ES2636937T3 - Procedimiento de preparación de un intermediario de pirimidina - Google Patents
Procedimiento de preparación de un intermediario de pirimidina Download PDFInfo
- Publication number
- ES2636937T3 ES2636937T3 ES14737272.6T ES14737272T ES2636937T3 ES 2636937 T3 ES2636937 T3 ES 2636937T3 ES 14737272 T ES14737272 T ES 14737272T ES 2636937 T3 ES2636937 T3 ES 2636937T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- compound
- preparation procedure
- pyrimidine intermediate
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title abstract description 4
- 238000002360 preparation method Methods 0.000 title description 8
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 6
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 abstract 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 abstract 1
- 239000008346 aqueous phase Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000000622 liquid--liquid extraction Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940043265 methyl isobutyl ketone Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000000638 solvent extraction Methods 0.000 abstract 1
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 description 3
- 229960001039 macitentan Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Detergent Compositions (AREA)
- Magnetic Heads (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Extraction Or Liquid Replacement (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Manufacturing Cores, Coils, And Magnets (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13176374 | 2013-07-12 | ||
| EP13176374 | 2013-07-12 | ||
| PCT/EP2014/064904 WO2015004265A1 (en) | 2013-07-12 | 2014-07-11 | Process for preparing a pyrimidine intermediate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2636937T3 true ES2636937T3 (es) | 2017-10-10 |
Family
ID=48790244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14737272.6T Active ES2636937T3 (es) | 2013-07-12 | 2014-07-11 | Procedimiento de preparación de un intermediario de pirimidina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9556125B2 (enExample) |
| EP (1) | EP3019479B1 (enExample) |
| JP (1) | JP6375374B2 (enExample) |
| KR (1) | KR102305298B1 (enExample) |
| CN (1) | CN105636940B (enExample) |
| AR (1) | AR096865A1 (enExample) |
| CA (1) | CA2915736C (enExample) |
| DK (1) | DK3019479T3 (enExample) |
| ES (1) | ES2636937T3 (enExample) |
| HR (1) | HRP20171166T1 (enExample) |
| HU (1) | HUE034071T2 (enExample) |
| IL (1) | IL243477B (enExample) |
| MX (1) | MX360768B (enExample) |
| PL (1) | PL3019479T3 (enExample) |
| PT (1) | PT3019479T (enExample) |
| TW (1) | TWI643848B (enExample) |
| WO (1) | WO2015004265A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA201605808B (en) | 2015-08-26 | 2017-08-30 | Cipla Ltd | Process for preparing an endothelin receptor antagonist |
| CN105461638A (zh) * | 2015-12-10 | 2016-04-06 | 合肥久诺医药科技有限公司 | 一种马西替坦晶型及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100432070C (zh) * | 2000-12-18 | 2008-11-12 | 埃科特莱茵药品有限公司 | 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用 |
| CN103724281A (zh) * | 2013-12-03 | 2014-04-16 | 镇江圣安医药有限公司 | N-[5-（4-溴苯基）-6-[2-[（5-溴-2-嘧啶基）氧基]乙氧基]-4-嘧啶基]-n′-丙基磺酰胺的新型衍生物及其应用 |
| CN103819411A (zh) * | 2014-03-14 | 2014-05-28 | 成都克莱蒙医药科技有限公司 | 一种马西替坦中间体新的制备方法 |
-
2014
- 2014-07-10 AR ARP140102549A patent/AR096865A1/es active IP Right Grant
- 2014-07-11 CA CA2915736A patent/CA2915736C/en active Active
- 2014-07-11 KR KR1020167003201A patent/KR102305298B1/ko not_active Expired - Fee Related
- 2014-07-11 DK DK14737272.6T patent/DK3019479T3/en active
- 2014-07-11 US US14/904,657 patent/US9556125B2/en active Active
- 2014-07-11 CN CN201480039832.2A patent/CN105636940B/zh active Active
- 2014-07-11 TW TW103124052A patent/TWI643848B/zh not_active IP Right Cessation
- 2014-07-11 PT PT147372726T patent/PT3019479T/pt unknown
- 2014-07-11 EP EP14737272.6A patent/EP3019479B1/en active Active
- 2014-07-11 WO PCT/EP2014/064904 patent/WO2015004265A1/en not_active Ceased
- 2014-07-11 MX MX2016000386A patent/MX360768B/es active IP Right Grant
- 2014-07-11 ES ES14737272.6T patent/ES2636937T3/es active Active
- 2014-07-11 HR HRP20171166TT patent/HRP20171166T1/hr unknown
- 2014-07-11 JP JP2016524837A patent/JP6375374B2/ja active Active
- 2014-07-11 HU HUE14737272A patent/HUE034071T2/en unknown
- 2014-07-11 PL PL14737272T patent/PL3019479T3/pl unknown
-
2016
- 2016-01-06 IL IL243477A patent/IL243477B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP3019479B1 (en) | 2017-05-10 |
| KR20160030972A (ko) | 2016-03-21 |
| KR102305298B1 (ko) | 2021-09-27 |
| US9556125B2 (en) | 2017-01-31 |
| JP2016525094A (ja) | 2016-08-22 |
| MX2016000386A (es) | 2016-04-29 |
| IL243477B (en) | 2018-06-28 |
| PL3019479T3 (pl) | 2017-10-31 |
| US20160145215A1 (en) | 2016-05-26 |
| TWI643848B (zh) | 2018-12-11 |
| HRP20171166T1 (hr) | 2017-10-06 |
| DK3019479T3 (en) | 2017-07-17 |
| CN105636940B (zh) | 2018-02-27 |
| WO2015004265A1 (en) | 2015-01-15 |
| MX360768B (es) | 2018-11-15 |
| CA2915736C (en) | 2021-07-27 |
| EP3019479A1 (en) | 2016-05-18 |
| AR096865A1 (es) | 2016-02-03 |
| HUE034071T2 (en) | 2018-01-29 |
| CA2915736A1 (en) | 2015-01-15 |
| JP6375374B2 (ja) | 2018-08-15 |
| CN105636940A (zh) | 2016-06-01 |
| TW201536759A (zh) | 2015-10-01 |
| PT3019479T (pt) | 2017-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6640255A2 (es) | Activadores de guanilato ciclasa soluble | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| CO6811860A2 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
| ECSP14006132A (es) | Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih | |
| ECSP14013189A (es) | Inhibidores de la replicación de los virus de la gripe | |
| BR112015015031A2 (pt) | processo de glicoconjugação | |
| BR112013023876A2 (pt) | derivados de pirroltriazinona como inibidores de pi3k | |
| MX2015012731A (es) | Procesos e intermedios para preparar un medicamento. | |
| ECSP13012438A (es) | Proceso para preparar compuestos antivirales | |
| CO6920294A2 (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| BR112015019590A2 (pt) | derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv | |
| MX2014005342A (es) | Inhibidores del virus de la hepatitis c. | |
| CU20120137A7 (es) | Hidrato del hidrocloruro de agomelatina y preparación de éste | |
| CL2014003012A1 (es) | Formulación en capsulas que comprende al menos un compuesto de formula (i), solubilizado; metodo de administracion de la formulacion; uso para tratar una infeccion por el virus de la hepatitis c. | |
| BR112013024965A2 (pt) | composto, composição farmacêutica, método de tratamento de infecções virais, e, processo para preparar um composto | |
| NI201800071A (es) | Compuestos de isoindol | |
| BR112015010271A8 (pt) | produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos | |
| AR086987A1 (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
| ES2636937T3 (es) | Procedimiento de preparación de un intermediario de pirimidina | |
| ES2571043T3 (es) | Preparación de dihidropiridinas | |
| ECSP12012156A (es) | Hidrato del hidrobromuro de agomelatina y | |
| BR112014003730A2 (pt) | processo para a preparação de derivados de tietano | |
| CO2017000010A2 (es) | Proceso para la preparacion de ácidos 3-hidroxipicolínicos | |
| GT201100241A (es) | Proceso para preparar compuestos antivirales | |
| BR112015012843B8 (pt) | Método para sintetizar o composto |